https://www.selleckchem.com/products/zeocin.html
Overall, overdosage was recorded in 7.15% of all DPP4i treatments. In advanced stages (IIIb, IV, and V), overdosage was much higher (36.8% for all DPP4is, and 58.7% if linagliptin is excluded). Under real-world clinical practice conditions, more than one third of T2DM patients with advanced renal failure were overdosed with DPP4is because the doses were not adequately adjusted to the glomerular filtration rate of each patient. Under real-world clinical practice conditions, more than one third of T2DM patients with advanced renal failure
Curtir
Comentario
Compartilhar
